# Vedolizumab for the Treatment of Collagenous Gastritis

> **NCT06317220** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 11 (actual)

## Conditions studied

- Collagenous Gastritis

## Interventions

- **BIOLOGICAL:** Vedolizumab

## Key facts

- **NCT ID:** NCT06317220
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2025-12
- **Final completion:** 2026-10
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-12-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317220, "Vedolizumab for the Treatment of Collagenous Gastritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06317220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*